C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.330
+0.090 (4.02%)
At close: Aug 13, 2025, 4:00 PM
2.340
+0.010 (0.43%)
After-hours: Aug 13, 2025, 7:59 PM EDT
C4 Therapeutics Revenue
C4 Therapeutics had revenue of $6.46M in the quarter ending June 30, 2025, a decrease of -46.17%. This brings the company's revenue in the last twelve months to $34.24M, up 16.55% year-over-year. In the year 2024, C4 Therapeutics had annual revenue of $35.58M with 71.44% growth.
Revenue (ttm)
$34.24M
Revenue Growth
+16.55%
P/S Ratio
4.61
Revenue / Employee
$311,273
Employees
110
Market Cap
165.83M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CCCC News
- 6 days ago - C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - C4 Therapeutics: An Entry Point If There's Ever Going To Be One - Seeking Alpha
- 3 months ago - C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 months ago - C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 months ago - C4 Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 8 months ago - C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader - GlobeNewsWire
- 9 months ago - C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewsWire
- 10 months ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire